辛伐他汀、依折麦布联合应用治疗高脂血症的临床价值

来源 :兵团医学 | 被引量 : 0次 | 上传用户:scsnlaosi
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
目的:观察应用选择性胆固醇吸收抑制剂依折麦布治疗高脂血症的临床疗效。方法:选择高脂血症患者50例,随机分为辛伐他汀组(对照组)25例和辛伐他汀加依折麦布组(治疗组)25例,治疗8周,观察2组患者治疗前后血脂变化。结果:治疗组患者血脂达标率显著优于对照组(P<0.05);2组患者治疗后TC、LDL-C较治疗前降低,且治疗组治疗后较对照组治疗后改善更加(P<0.05)。结论:应用选择性胆固醇吸收抑制剂依折麦布联合他汀类治疗高脂血症疗效显著。 Objective: To observe the clinical efficacy of selective elective cholesterol absorption inhibitor ezetimibe in the treatment of hyperlipidemia. Methods: Fifty patients with hyperlipidemia were randomly divided into simvastatin group (control group) 25 and simvastatin plus ezetimibe group (treatment group) 25 cases for 8 weeks, the two groups were treated Changes in blood fat before and after. Results: The blood lipid compliance rate of the treatment group was significantly better than that of the control group (P <0.05). The TC and LDL-C of the two groups were lower than those before treatment, and the treatment group improved more than the control group after treatment (P <0.05 ). Conclusion: The selective cholesterol absorption inhibitor ezetimibe and statins for the treatment of hyperlipidemia have a significant effect.
其他文献
Humans in Space suffer from microgravity-induced muscle atrophy and attenuated bone strength. High-frequency, low-amplitude vibration has been proposed as a tre
We perform first-principles calculation to study the transport properties of the acid dopped on C(4,4) carbon nanotube coupled to two C(4,4) carbon nanotube ele
目的:探讨流产后不孕症的危险因素。方法回顾性分析76例人工流产后不孕症患者的临床资料,了解其主要影响因素。结果继发性不孕症主要原因包括急、慢性盆腔炎26例(34.1%,26/76)、
目的:探讨逐步后退法与常规法在根管预备中的治疗效果比较。方法:选取2011年6月~2013年6月来我院接受治疗的100例临床感染根管病例,随机将其分为观察组和对照组各50例,给予观察组
人工流产术引起的疼痛是孕妇难以忍受的,由于孕妇对人流疼痛的恐惧,精神过度紧张,不能配合医师的手术操作,导致流产吸宫不全或子宫穿孔等并发症。本文介绍我科100例应用国产麻醉
肺炎支原体(mycoplasma pneumoniae,MP)是引起小儿呼吸道疾病的常见病原体之一,亦可导致心、肝、肾、胃肠道、脑、血液等肺外各种器官损害。自20世纪90年代以来,随着呼吸道感
目的:观察多索茶碱治疗支气管哮喘的临床疗效,指导临床用药。方法:采取随机分组的原则,共收集110例支气管哮喘患者分为两组,其中治疗组55例;对照组55例。治疗组予以多索茶碱
脑卒中是突然发生的急性脑血液循环障碍性疾病,是四高性疾病,即发病率高,病死率高,致残率高,再发率高.已成为我国居民第一位死因,40岁以下脑卒中发病占全部脑卒中的10%~20%[1]随